Strategic $6 million capital infusion via warrant exercise underscores continued conviction in FIZE Medical's growth across leading ICUs worldwide.

战略性地通过行使认股权注入600万美元资本，彰显了对FIZE Medical在全球领先ICU中增长的持续信心。

NEW YORK

纽约

,

，

March 30, 2026

2026年3月30日

/PRNewswire/ --

/PRNewswire/ --

FIZE Medical

菲泽医疗

, a medical technology company focused on smart fluid management in critical care, today announced the exercise of stock warrants totaling $6 million by select existing investors. The exercise – made at the original warrant price – reflects strong conviction from the company's investor base in FIZE Medical's commercial trajectory and its mission to redefine fluid management in the ICU..

，一家专注于重症监护智能液体管理的医疗技术公司，今天宣布部分现有投资者行使了总计600万美元的股票认股权证。该行使价为原始认股权证价格，反映了公司投资者对FIZE Medical商业轨迹及其重新定义ICU液体管理使命的强烈信心。

Continue Reading

继续阅读

Dror Zerem, Chief Executive Officer, FIZE Medical

Dror Zerem，首席执行官，FIZE Medical

The proceeds will be deployed to accelerate commercial adoption of the FIZE kUO in the Japanese, European and U.S. markets, further R&D for next-generation AI-driven fluid management, and expand clinical validation studies within leading hospitals, all to advance the company's vision of transforming fluid management from reactive to proactive..

这笔资金将用于加速FIZE kUO在日本、欧洲和美国市场的商业应用，推动下一代人工智能驱动的液体管理技术的研发，并在领先医院内扩展临床验证研究，以实现公司将液体管理从被动转变为积极主动的愿景。

'This $6 million investment is a powerful vote of confidence from our partners – not just in our technology, but in FIZE's overall capabilities and our proven track record of delivering high-impact solutions to ICUs worldwide,' said Dror Zerem, CEO of FIZE Medical. 'With this capital, we are accelerating the development of predictive capabilities that will enable clinicians to intervene earlier and ultimately improve patient outcomes'..

“这600万美元的投资来自我们的合作伙伴，他们不仅对我们技术充满信心，也对FIZE的整体能力以及我们为全球ICU提供高影响力解决方案的可靠记录投下了强有力的信任票，”FIZE Medical首席执行官Dror Zerem表示。“通过这笔资金，我们正在加速开发预测功能，帮助临床医生更早进行干预，最终改善患者的治疗效果。”

The additional funding milestone takes FIZE Medical one step closer to its vision of transforming fluid management from reactive to proactive as part of its smart fluid management solutions

额外的融资里程碑使FIZE Medical更接近其将液体管理从被动转变为主动的愿景，这是其智能液体管理解决方案的一部分。

About FIZE Medical:

关于FIZE医疗：

FIZE Medical is an innovative MedTech company dedicated to transforming fluid management for critically ill patients. Its proprietary FIZE kUO® system, commercially available in the U.S., provides real-time, digital monitoring to support precision fluid management, early intervention, and improved patient outcomes.

FIZE Medical是一家创新的医疗技术公司，致力于改变危重病人的体液管理。其专有的FIZE kUO®系统已在美国上市，提供实时、数字化监测，以支持精确的体液管理、早期干预和改善患者预后。

FIZE Medical is committed to redefining fluid management through continuous innovation, AI-driven data insights, and clinical evidence..

FIZE Medical 致力于通过持续创新、人工智能驱动的数据洞察和临床证据重新定义液体管理。

www.fizemedical.com

www.fizemedical.com

Media Contact:

媒体联系人：

Eran Blankenstein

埃兰·布兰肯斯坦

[email protected]

电子邮件地址

Photo:

照片：

https://mma.prnewswire.com/media/2945319/Dror_Zerem_CEO_FIZE_Medical.jpg

https://mma.prnewswire.com/media/2945319/Dror_Zerem_CEO_FIZE_Medical.jpg

SOURCE FIZE Medical

来源：FIZE医疗

21

21

%

%

more press release views with

更多新闻稿浏览量与

Request a Demo

请求演示